Cresset Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cresset Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,305	Closed	-$511K	–	1117
2022 Q1	$511K	Sell	4,305 -787	-15%	-$98.2K	0.01%	602
2021 Q4	$702K	Buy	5,092 +568	+13%	+$72.2K	0.01%	576
2021 Q3	$628K	Sell	4,524 -2	-0%	-$250	0.01%	538
2021 Q2	$439K	Buy	+4,526	New	+$367K	0.01%	607

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cresset Asset Management's BHVN Position: Q2 2022 in Review

Cresset Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 4,305 shares — an estimated $511K sold.

Cresset Asset Management first reported a position in BHVN in Q2 2021 and held it in 4 quarters. The position peaked at $702K in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Cresset Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Cresset Asset Management sold 4,305 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $511K.
Cresset Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2021 and held it in 4 quarters.
Cresset Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $702K in Q4 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Cresset Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.